Vous venez de lire:

Crescita Therapeutics™ Reports 2018 Third Quarter Results Strong Royalty Revenue and Achievement of First Pliaglis US Sales Milestone Positive Adjusted EBITDA of $0.8M

Nouvelles fournies par

Crescita Therapeutics Inc.

Nov 09, 2018, 07:30 ET